← Eichor
Study identifier: NCT05611502 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Influence of TMS on Attention Modulation

Condition: Drinking, Alcohol  ·  Sponsor: Auburn University

PhaseNA
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to help understand how attention processes influence brain engagement during emotion and social cognition. The investigators also want to know if these processes are associated with drinking alcohol. Participation includes three study visits of about 2 hours each over approximately a month. The first visit involves a magnetic resonance imaging (MRI) scan and answering survey questions. Each of the next two visits will involve a session of transcranial magnetic stimulation (TMS, a non-invasive brain stimulation technique) followed by another MRI scan. People in the Auburn/Opelika area 19 or older are eligible to participate. People who drink alcohol and people who do not drink or don't drink very much are invited to participate.

This description comes directly from the study's public registry record.

Talk to the study team

SCAMPI Lab  ·  334-521-2807  ·  scampi@auburn.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Auburn UniversityAuburn, Alabama, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05611502